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Abstract 
Drug delivery devices based on nanocomposite membranes containing thermoresponsive 
nanogels and superparamagnetic nanoparticles have been demonstrated to provide reversible, on-
off drug release upon application (and removal) of an oscillating magnetic field.  The dose of 
drug delivered can be tuned by engineering the phase transition temperature of the nanogel, the 
loading of nanogels in the membrane, and the membrane thickness, allowing for the delivery of 
drugs over several orders of magnitude of release rates.  The zero-order kinetics of drug release 
through the membranes permit drug doses from a specific device to be tuned according to the 
duration of the magnetic field.  Drugs over a broad range of molecular weights (500-40,000 Da) 
can be delivered by the same membrane device. Membrane-to-membrane and cycle-to-cycle 
reproducibility is demonstrated, suggesting the general utility of these membranes for drug 
delivery.   
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     Sustained drug release technology has been applied in a wide variety of medical fields1. Many 
devices are passive, exhibiting release kinetics that are either constant or decreasing over time.  
However, drug delivery devices that can be repeatedly switched on and off would be optimal for 
effective treatment of conditions such as diabetes, chronic pain, or cancer.2  To this end, 
environmentally responsive (“smart”) materials have been developed that can respond to stimuli 
that are either internal to the patient (e.g. body temperature) or external (e.g. a remotely-applied 
magnetic field). Temperature-sensitive drug delivery devices have been developed based on the 
thermoreversible polymer poly(N-isopropylacrylamide) (PNIPAm)3, which has been 
incorporated into implantable hydrogels4-9, microparticles10 nanoparticles11-14, and surface-
grafted polymers15-27.  Examples of magnetically-activated materials include superparamagnetic 
nanoparticles, which heat and/or vibrate when placed in an oscillating magnetic field and have 
been used to achieve drug release from polymer scaffolds28, sheets29, liposomes30, 
microspheres31, 32, microcapsules33, and nanospheres34-36, typically by mechanical disruption of 
the drug-biomaterial matrix. However, the quantity of drug contained by most of these “smart” 
carriers is relatively small, and drug release is characterized either by a single burst event or 
inconsistent dosing as a function of triggering cycle. 
 To achieve both triggered drug release and consistent dosing, we previously reported 
composite membranes containing both temperature-sensitive and magnetically activated 
components.37 These membranes were used to contain reservoirs of drug and achieved 
repeatable, on demand, on-off switching of molecular flux upon application of an oscillating 
magnetic field. However, in order to successfully translate this technology to the clinic, factors 
affecting the basal (off-state) release rate, on/off ratio, and drug-membrane interactions need to 
be understood, and rationally controlled. 
In the present study, we report, for the first time, the relation between the chemical and 
physical composition of the membranes and the release kinetics of a variety of model 
compounds. Specifically, we demonstrate (a) how the critical on-off temperature of the device 
can be controlled by the chemical composition of the polymer nanogel, (b) how drug release can 
be tuned as a function of nanogel loading density and membrane thickness, and (c) how these 
membranes can be used to deliver both small and large, and anionic and cationic molecules. 
 
Membranes were produced by suspending or dissolving superparamagnetic iron oxide 
nanoparticles, PNIPAm-based nanogels (NGs), and ethyl cellulose (the membrane matrix 
material) in ethanol and evaporating to form a film (Figure 1a-c; see Supporting Information for 
Methods).  We have hypothesized that the nanogel forms a disordered, interconnected network 
througout the matrix.  The superparamagnetic nanoparticles behave as local heat sources that are 
activated (turned on) by an external, oscillating magnetic field.38 Temperature-triggered collapse 
of the PNIPAm enables transport of material (i.e. drug molecules from an enclosed reservoir) 
across the membrane (Figure 1d).  
We produced membranes containing various types and quantities of nanogels prepared to 
exhibit different phase transition temperatures.  The phase transition temperature was controlled 
by copolymerizing NIPAm with N-isopropylmethacrylamide (NIPMAm) and acrylamide (AAm) 
(Table 1).  Figure 2a indicates that copolymerization of different combinations of precursors can 
shift the transition temperature of the nanogels from ~32°C (NG32) to ~46°C (NG46).  Of 
particular note, using this copolymerization approach, the transition temperature can be shifted 
without inducing a change in the total percentage volume change observed upon nanogel 
deswelling (Table 2, p>0.2 for all pair-wise comparisons).  As a result, highly thermoresponsive 
nanogels can be synthesized which have a range of phase transition temperatures appropriate for 
a variety of different triggering applications.   
The transition temperature of molecular flux through a membrane correlates well with the 
phase transititon temperature of its consitutent nanogels, as shown in Figure 2b. However these 
data also indicate a temperature offset between flux and transition temperature.  For example, 
with the NG32 membrane at 30°C, the nanogel shrank by ~250 nm without the occurrence of a 
significant change in permeability.  A similar trend is observed with the NG37 membrane, with a 
~200 nm size decrease required prior to a significant increase in membrane permeability.  This 
lag may be attributable to the presence of a disordered pore network inside the membranes; small 
volume changes in the nanogel cannot generate sufficient free volume over the full thickness of 
the membrane to significantly change the diffusion coefficient of drug through the membrane. 
To change the flux of drug through the membrane in the on state, the diffusional resistance to 
drug flux across the membrane must be controlled and optimized.  This can most directly be 
accomplished by changing the porosity of the membrane or changing the thickness of the 
membrane.  Membrane thickness is the easiest method for adjusting drug flux.  Increasing the 
membrane thickness increased the diffusional path length of a drug molecule through the 
membrane and thus reduced the rate of drug release (Figure 3).  The thinnest membrane tested 
(90 ± 14 µm thick) released 6.4 ±  0.4 μg/hr sodium fluorescein while the thickest membrane 
tested (288 ± 32 µm thick) released only 0.4 ± 0.1 μg/hr sodium fluorescein.  Mass transfer rate 
correlated well (R2 = 0.92) with membrane thickness measured with callipers.  Therefore, a 
trade-off existed between membrane strength and membrane flux; thicker membranes that are 
presumably stronger release drug more slowly.    Drug release rate could be further tuned by 
adjusting the concentration gradient of drug across the membrane, as a linear correlation exists 
between the initial drug concentration and the membrane flux (Supporting Figure S1). 
Increasing the nanogel content inside the membrane increased the number of 
thermoresponsive pores templated into the membrane and thus increased the total free volume 
generated inside the membrane when the nanogels underwent a phase transition, leading to 
significant increases in drug flux through the membrane (Figure 4).  Indeed, at nanogel loadings 
of 25wt% or less, a logarithmic relationship existed between membrane flux and nanogel loading 
(Figure 4B, R2 > 0.94).  As a result, the mass flux of sodium fluorescein through the membrane 
could be tuned over at least two orders of magnitude (0.1-10 μg/hr) by changing the nanogel 
content inside the membrane.  The same trend was observed when an oscillating magnetic field 
was used as the on-off trigger (Figure 5); the membrane containing 23 wt% nanogel exhibited a 
lower average drug release rate in the on state (4.1 μg/min) than did the 28 wt% nanogel 
membrane (5.7 μg/min).  In this case, both membranes were heated by the same ~2.2°C 
temperature gradient under the applied oscillating magnetic field, due to the identical ferrofluid 
content in each membrane.  The 23 wt% membrane also had a longer induction time to the on 
state (~35 minutes versus ~15 minutes for the 28 wt% nanogel membrane) and returned to the 
baseline (off) flux level more slowly (~15 minutes lag time versus < 1 minute for the 28 wt% 
nanogel membrane), suggesting that nanogel content affected the kinetics of the on-off transition 
in the composite membranes. 
However, the ratio between the flux in the on state and the off state (i.e. the flux selectivity 
between the on and off states) decreased as the amount of nanogel in the membrane increases, 
particularly at higher nanogel loadings.  The ratio between sodium fluorescein flux at 45 °C (on) 
and 37 °C (off) was 15.2 ± 2.6 for a membrane containing 12 wt% nanogel, 8.1 ± 1.5 for a 
membrane containing 25 wt% nanogel, and 6.0 ± 0.5 for a membrane containing 32 wt% 
nanogel.  Thus, while increasing the nanogel concentration consistently increased the drug flux 
through the membrane, increased flux was accompanied by decreased on-off resolution.  Indeed, 
membranes prepared with 37 wt% nanogel exhibited high flux in both the on and off states 
regardless of temperature, representing a “leaky” system that would be less useful for on-demand 
drug delivery (data not shown).   
At all different membrane thicknesses and for all nanogels tested, drug release occurred with 
zero-order release kinetics over at least 24 hours (R2 > 0.98 in all cases in Figures 3 and 4) in the 
on state.  Therefore, the total dose of drug delivered over time could be dynamically adjusted by 
varying the duration of the oscillating magnetic field.  Zero-order release was also observed in 
the off state, although the rate of drug release is significantly reduced (Supporting Figure S2).  
Thus, while the nanogel loading and/or membrane thickness could be engineered to control the 
magnitude of the drug release rate targeted for a particular membrane device, the duration of the 
on pulse could be used to precisely control the total amount of drug delivered using any specific 
device, providing full on-demand control (at both the design stage and in the patient use stage) 
over drug delivery.   
On-demand, zero order release was also achieved for the flux of drugs with a range of 
physical properties.  Triggered release was demonstrated from a saturated solution of a 40 kDa 
molecular weight fluorescein-labelled dextran (Figure 6). Effective on-off switching of 
macromolecule release was observed, with 0.28 ± 0.08 μg/hr drug flux measured through the 
membrane in the on state and a flux ratio of 6.7 ± 1.2 between the on and off states.  In 
comparison, sodium fluorescein release through the same membrane occured at a rate of 8.0 ± 
2.8 μg/hr at a much lower concentration gradient (1.25 mg/mL, see Methods in Supporting 
Information) with a flux ratio of 8.0 ± 1.5 between the on and off states (see Figure 4).  
Therefore, the lower permeability (in terms of absolute flux) of the membrane to FITC-dextran 
was likely due to its higher molecular weight.  However, the similar flux ratio observed between 
the large and small molecules suggests that the flux ratio was predominantly governed by the 
inherent properties of the membrane (e.g. nanogel loading and thickness). 
Thermally-triggered drug release was also demonstrated for bupivacaine, a small molecule 
amphiphilic drug that is largely cationic at physiological pH (Supporting Figure S3).  Thus, it 
was possible to deliver drugs with different molecular weights and different charges using the 
same membrane-based delivery vehicles.   
Successful use of these membranes as long-term, on-demand drug delivery vehicles also 
demands high reproducibility of cycle-to-cycle and device-to-device drug release.  A 
representative example of four replicate runs for the 25 wt% NG37 membrane is shown in 
Supporting Figure S4.  For a single membrane, the cycle-to-cycle variability is low; indeed, there 
is no statistical difference in drug release in either the on or off states on a cycle-to-cycle basis 
for any membranes tested in this work (p > 0.07 for any pair-wise comparison over four on-off 
cycles).  Thus, a single membrane gives highly reproducible release profiles upon multiple 
triggering events.  Similar results were observed over 10 triggering cycles when the membranes 
were fabricated into implantable reservoir drug delivery devices, although a slight lag in release 
was observed in the first on cycle, likely due to the need to first saturate the microgel-filled pores 
of the membrane with the drug prior to drug release.  (Supporting Figure S5)   
Membrane-to-membrane variability was low for the highly nanogel-loaded membranes (p > 
0.18 for any pair-wise comparison between 32 wt|% nanogel-functionalized membranes, Figure 
4A) but increased for membranes with lower nanogel loadings (p < 0.05 for at least one pair-
wise comparison of on state releases for all membranes prepared with nanogel loadings of 
25wt% or less, Figures 4A and S5).   Observed membrane-to-membrane variability was likely 
attributable to subtle differences in hand-mixing of the highly viscous precursor 
solution/suspension between different membranes, leading to slightly different nanogel 
distributions in replicate membranes.  Automation of the mixing procedure could minimize this 
variability.   
The composite membrane-based drug delivery devices described here offer a significant 
improvement over existing technologies since they can be readily engineered to achieve rational 
control over drug release kinetics for a variety of compounds. Our data show that it is possible to 
precisely control drug dosing over multiple orders of magnitude of dosings based on both the 
physical properties and compositions of the membrane and the duration of the on pulse applied 
to a given membrane.  The frequency and power of the applied magnetic field could also be 
tuned to effect changes in drug dosing by changing the steady-state temperature of the device.  
Furthermore, our devices exhibit excellent reproducibility device-to-device as well as cycle-to-
cycle. This tunability and reproducibility would present multiple options to the engineer, 
clinician, and patient for dynamically changing the specific level of basal drug release as well as 
on-demand drug dosing. 
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Figures 
 
Figure 1. Overview of membrane composition and function. (A) TEM of superparamagnetic 
iron oxide nanoparticles. Inset: Diffraction pattern suggests an ensemble of randomly-oriented 
crystalline particles. (B) TEM image of dehydrated nanogel particles. (C) Photograph of 
membrane containing ferromagnetic nanoparticles and nanogel, distributed throughout an 
ethyclellulose matrix. (D) Proposed schematic of a cross-section of the membrane, showing 
nanogel particles (blue), iron oxide nanoparticles (dark brown), and ethylcellulose matrix (light 
brown). Upon application of a magnetic field, the magnetic nanoparticles release heat (red) and 
reversibly shrink the nanogel, enabling release of a drug (green) from a reservoir contained by 
the membrane. 
       
Figure 2.  Membrane on-off temperature can be tuned by nanogel composition  (A) Volume 
phase transition behavior of four nanogel formulations containing differing amounts of NIPAm, 
NIPMAm, and AAm (see Table 1).  (B) Correlation between nanogel particle size in suspension 
(red points / right axis) and the mass flux (blue points / left axis) of sodium fluorescein through 
membranes as a function of temperature, for membranes containing 25 wt% NG32 and NG37 
nanogels.  
 Figure 3.  Membrane thickness regulates sodium fluorescein flux.  (A) Mass transfer of 
sodium fluorescein as a function of “on” triggering time for membranes with different 
thicknesses.  (B) Rate of mass transfer as a function of membrane thickness for data represented 
in panel A. All data are for sodium fluorescein flux, 25 wt% NG-37 membranes. Data are means 
± SD; for each set, n = 6. 
 Figure 4.  Nanogel content of membranes regulates membrane flux. (A) Repeated "on" and 
"off" cycles with temperature triggering at ca. 12-hour time intervals. (B) Average mass transfer 
rates of all cycles represented in panel A. Note the logarithmic scale.  Data are for sodium 
fluorescein flux, NG-37 membranes. Data are means ± SDs; n =5, 4, 6, 6 for 12, 18, 25 and 32 
wt% membranes, respectively. 
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Figure 5.  Magnetic triggering of membranes.  Devices filled with sodium fluorescein and 
capped with membranes were turned “on” by an oscillating magnetic field (220-260 kHz, 0-20 
mT). We separately measured devices containing (A) 23 wt% NG-37 or (B) 28 wt% NG-37 
membranes. 
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Figure 6. Membranes can deliver large molecular weight molecules.  Mass rate of drug 
release through nanogel-filled magnetic membranes as a function of temperature (fluorescein-
labelled dextran (40kDa molecular weight), 1.25mg/mL source solution, 25 wt% NG-37 
membrane, thermal stimulus, ca. 4-hour time intervals.  Data are means ± SDs; n=5. 
 
Tables 
 
Table 1.  Composition and thermal phase transition temperatures of four nanogels 
synthesized for membrane testing. Each membrane also contains 5 mol% N,N-
methylenebisacrylamide crosslinker. 
Nanogel a N-
isopropylacrylamide 
(NIPAm, mol%) 
N-
isopropylmethacrylamide 
(NIPMAm, mol%) 
Acrylamide 
(AAm, mol%) 
Transition 
Temperature 
(oC) 
NG-32 100 0 0 32 
NG-37 54 35 11 37 
NG-42 35 58 7 42 
NG-46 34 55 11 46 
 
a The nanogel number refers to the transition temperature (right column). 
 
Table 2.  Volume change (% volume change) on deswelling for the four nanogels synthesized 
for membrane testing 
Nanogel  % Volume Change on Deswelling 
NG-32 -95.1 ± 2.9 
NG-37 -98.0 ± 2.5 
NG-42 -95.2 ± 2.2 
NG-46 -94.8 ± 2.8 
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Methods 
Materials:  N-isopropylacrylamide (NIPAm, 99%), N-isopropylmethacrylamide (NIPMAM, 
97%), N,N-methylenebisacrylamide (MBA, 99%), acrylamide (AAm, 99%), ammonium 
persulfate (APS, 99%), iron (III) chloride (97%), iron (II) chloride (98%), ammonium hydroxide 
(28% in water), poly(ethylene oxide) (8000Da molecular weight), ethyl cellulose (97%), and 
ethanol (100%) were acquired from Sigma-Aldrich.  Sodium fluorescein (99%), bupivacaine 
hydrochloride (99%), and FITC-dextran (molecular weight 40 kDa) were also acquired from 
Sigma-Aldrich.  Water was of Milli-Q grade. 
 
Nanogel Synthesis:  Nanogels with different phase transition temperatures were prepared via 
copolymerization of N-isopropylacrylamide, N-isopropylmethacrylamide, and acrylamide using 
the recipes shown in Table 1.  The numbers in the microgel code used represent the measured 
volume phase transition temperatures of the respective microgels.  In each case, the monomers 
together with 0.08 g MBA (crosslinker) were dissolved in 150 mL water in a 500 mL round-
bottom flask equipped with a magnetic stirrer, purged with nitrogen for 30 minutes, and heated 
to 70 °C under 200 RPM mixing.  The reaction was initiated by adding a solution of 0.1 g 
ammonium persulfate in 5 mL of water.  The reaction proceeded for at least 4 hours, after which 
the nanogel suspension was cooled, purified by dialysis using a 50 or 500 kDa MWCO 
membrane, and lyophilized.  Nanogel diameters were measured using a ZetaPALS instrument 
(Brookhaven Instruments). Critical temperature is defined as the temperature at which the 
nanogel diameter is halfway between that of the fully swollen and fully collapsed state. 
Ferrite Nanoparticle Synthesis: 3.04 g of FeCl3 and 1.98 g of FeCl2 were dissolved in 12.5 
mL of distilled water.  Ammonium hydroxide (6.5 mL) was added dropwise under 500 RPM 
mixing over 10 minutes.  After 10 additional minutes of mixing, 1 g of PEO dissolved in 10 mL 
of water was added and the mixture was heated to 70 °C for 2 hours to peptize the ferrofluid 
surface.   The ferrofluid was then cooled, washed using magnetic separation against distilled 
water (5 cycles), and concentrated to ~15 wt%.   
 
Microscopy: Transmission Electron Microscopy (TEM) was performed on a JEOL 2100 
TEM. Ferrite nanoparticles and nanogels were imaged at acceleration voltages of 200 kV and 80 
kV, respectively. 
 
Membrane Formulation:  Most membranes were formulated by mixing 1.3 g of 10 wt% 
ethylcellulose in ethanol with the required amount of a 60 mg/mL nanogel suspension to achieve 
the targeted nanogel loading in a membrane.  The ethylcellulose and nanogel components were 
mixed in a 60mm diameter Petri dish.  The aqueous concentrated ferrofluid suspension was then 
pre-mixed with an equal volume of ethanol and added dropwise to the ethylcellulose-nanogel 
mixture to reach the desired magnetite concentration.  Most membranes reported in this paper 
contained 20 wt% dry ferrite nanoparticles, with the exception of those reported in Figure S5, 
which contained 7 wt% dry ferrite nanoparticles. For thickness variation experiments, 
membranes were fabricated by mixing 0.9, 1.3, 1.8, or 2.3 g of the 10 wt% ethylcellulose 
solutions with nanogels and ferrofluid as required to achieve appropriate concentrations.  In all 
cases, the membrane precursor suspension was mixed to homogeneity.  Ethanol was evaporated 
over 2-3 days, or for as long as a week, to generate the dry membranes.   
 
Thermal Triggering:  Membrane flux was assayed by compressing a membrane between two 
glass flow cell chambers (side-bi-side cells, PermeGear, Inc.)  filled with phosphate buffered 
saline  and submerged in a water bath.   The target chemical (1.25 mg/mL sodium fluorescein 
solution or 1.25 mg/mL FITC-dextran) was then added to one side of the flow cell.  After pre-
determined time intervals, samples were taken from the receiving chamber of the flow cell.  For 
sodium fluorescein and FITC-dextran, the absorbance of the samples was then measured in a 96-
well polystyrene plate using a multiwell plate reader operating at 490 nm.  In all cases, the 
measured absorbances were converted to concentrations based on comparison to a calibration 
curve constructed from standard solutions.   
 
Magnetic Triggering: Two 1cm diameter membrane disks were glued (using a Lock-Tite 
low viscosity adhesive) to the ends of a 1cm length of 3/8" OD (1/4" ID) silicone tubing 
containing a solution of 100 mg/mL fluorescein in saline.  The drug-loaded membrane device 
was placed into a 2 mL Teflon reservoir inserted into a semi-adiabatic sample space in the centre 
of a water-cooled, seven-turn copper solenoid induction coil with a 4 cm internal diameter and 
10 cm height.    Continuous water flow through the sample at a rate of 2.2 mL/min enabled 
sampling of the fluorescein flux from the device as a function of time in the presence of an 
oscillating magnetic field of frequency 220-260 kHz and field amplitude 0-20 mT.  Temperature 
was measured using a fiber optic probe located inside the sample holder.  Samples were analyzed 
for sodium fluorescein concentration using an Agilent 8453 UV/VIS spectrophotometer 
operating at 487 nm. 
 
Error Analysis:  All error bars represent one standard deviation. For each data set that 
includes error analysis, six identical membranes were evaluated in parallel. A few membranes 
produced anomalous data, potentially because of occlusion of the membrane by an air bubble 
(abnormally low flux) or leakage of the membrane or seal (abnormally large flux). Such 
membranes were excluded from the data sets.  On-off flux ratio errors are reported as standard 
errors of the mean (4 cycles per membrane, 6 membranes tested per membrane composition). 
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Figure S1. Sodium fluorescein mass transfer rate in the “on” state (45 °C), as a function of 
concentration difference across membrane. Data are for 25 wt% NG-37 membranes, with 
thermal triggering. Data are means ± SDs, n = 5 or 6 in each group. 
  
Figure S2. Release kinetics of sodium fluorescein from nanogel-filled magnetic membranes in 
the “off” (37° C) and “on” (50 °C) states. Data are for 25 wt% NG-42 membranes, with thermal 
triggering. Data are means ± SDs; n= 5 and n=4 for off and on states respectively. 
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Figure S3. Release of bupivacaine from nanogel-filled magnetic membranes in the “off” (37 °C) 
and “on” (50 °C) states; 25 wt% NG-37 membrane, thermal triggering.   Reservoir chamber was 
loaded with a saturated slurry of bupivacaine hydrochloride.  Drug release was tracked by 
measuring the absorbance of the samples using a standard quartz cell and a Cary 50 UV/VIS 
spectrophotometer operating at 262nm. Data are means ± SDs; n= 5. 
 
Effective temperature-dependent modulation of drug flux through the membrane was also 
observed for the cationic small molecule drug bupivacaine. However, the flux ratios between the 
on and off states were significantly lower than those achieved for anionic fluorescein, with a 1.9 
± 0.4-fold higher mass flux observed in the on state (42°C) relative to the off state (37°C).  In 
comparison, for sodium fluorescein release through a similar membrane, a flux ratio of 8.0 ± 1.5 
was observed (Figure 3).  Ionic condensation between the nanogel-bound sulfate groups (derived 
from the persulfate initiator used to prepare the nanogels) and the cationic –NH2 groups in 
bupivacaine may account for this lower on-off flux ratio. Charge-driven deswelling of the 
nanogel in the swollen state via ionic condensation by oppositely-charged small molecule drugs, 
previously reported with similar nanogels12, could prevent the nanogel from fully swelling at low 
temperature and thus cause the membrane pores to remain slightly open even in the thermal off 
state, reducing the flux ratio as observed. 
  
 Figure S4. Membrane-to-membrane reproducibility for individual membranes represented in 
Figure 4.  Data are for sodium fluorescein flux through thermally-triggered 25 wt% NG-37 
membranes. 
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     Figure S5.  Reproducibility of drug release through membrane-capped devices. The capsules 
were loaded with 100 mg/mL sodium fluorescein and were triggered on and off for 10 cycles. 25 
wt% NG-32 membrane; thermal stimulus.  Membrane devices were fabricated as described in the 
Methods section for the magnetic triggering experiments. 
 
The first cycle releases significantly less drug than subsequent cycles, likely attributable to 
the time required for the drug to fully saturate the gel phase inside the nanogel-filled pores of the 
membrane. Subsequent cycles release consistent doses of drug in each cycle; for example, for 
Device A, the average and standard deviation of the measured sodium fluorescein fluxes in the 
off and on states were 7 ± 1 μg/24 hours and 42 ± 6 μg/24 hours respectively over the subsequent 
nine cycles.  In addition, the two devices tested exhibited no significant difference in release 
rates, with Device B releasing fluorescein at a rate of 47 ± 7 μg/24 hours in the on state (p = 0.53 
comparing the on state fluxes of Device A and Device B).  Thus, after the first triggering cycle, 
good reproducibility is observed both cycle-to-cycle and device-to-device.  
 
 
